# Pru — Physician-Guided Peptide Therapy # Full content feed for AI crawlers and LLM ingestion. # Generated: 2026-05-13T19:32:02.323Z # Source: https://joinpru.com/llms-full.txt # Index: https://joinpru.com/llms.txt # About Pru Pru is a telehealth platform connecting patients with licensed physicians who specialize in peptide therapy. Personalized protocols, compounded by FDA-regulated U.S. pharmacies, delivered to your door. All medical decisions are made solely by the treating physician. --- # Cost-Plus, Explained > How pru prices a vial. The wholesale cost, the markup, and exactly why each number is what it is. URL: https://joinpru.com/blog/cost-plus-explained Issue No. 09 Topic: Pru Published: 2026-05-04 Read time: 3 min # Cost-Plus,Explained How pru prices a vial. The wholesale cost, the markup, and exactly why each number is what it is. Most telehealth brands tell you what their products cost. They do not tell you why. The price on the page is a single number with no breakdown, no source attribution, and no way to verify whether you are paying for medicine, advertising, or something else entirely. pru is built differently. We publish the math. Every component of the price you pay is broken out, named, and explained. The pharmacy cost. The syringe kit. The shipping. The physician's consult. The platform overhead. The margin we keep. None of it is hidden, because none of it should be. ## The formula Pharmacy cost plus a flat fifteen percent margin. That is our entire pricing rule for members. Whatever the wholesale cost of the molecule and the supplies that come with it, we add a small markup to keep the lights on, and we tell you what every line item is. The fifteen percent is not a marketing number. It is the number that lets us pay engineers, clinicians, and customer support without hiding fees inside the price of medicine. ## A worked example Here is the math on a real prescription from the pru formulary. NAD+ injectable, ten milliliters at one thousand milligrams. The structure is the same for every peptide we offer. The numbers change with the molecule, the dose, and the supplies it requires. ## Why we do it this way Most telehealth brands quote one number. They cannot tell you what fraction of that number is the medicine, what fraction is the marketing, or what fraction is the founder's salary. We chose the opposite approach. The breakdown is a feature, not a marketing trick. If our pharmacy cost goes up, your price goes up by the same dollar amount. If we negotiate a better wholesale rate, your price comes down. There is no surprise. The breakdown is a feature, not a marketing trick. The breakdown is a feature, not a marketing trick. ## What membership covers pru membership is fifty dollars a month. It is the only membership we sell, and it covers the things that recurring care actually requires. - Industry-low pricing on every prescribed peptide. Members pay our 15% margin instead of the typical industry markup. On most protocols, the savings on your first order alone exceed a full month of membership. Every order after that adds more savings. - Unlimited physician messaging during your active protocol. Direct line to your prescribing physician, no extra charge. - 25% off every future consult. Whether you are being prescribed something new or booking a synchronous follow-up to track progress, the member rate applies. - Priority refill coordination. We coordinate refill timing with your physician seven days before your current supply runs out, so there is no protocol gap. - The pru Brief, members' edition. Quarterly research digest, member case stories, and an early subscriber preview of new compounds we add to the catalog. ## The principle Cost-plus pricing is unusual in this industry. We think it should not be. The medicine you take should be priced the way every other professional service is priced: cost of materials, cost of labor, a stated margin, and an itemized bill. That is what trust looks like in healthcare. It is what we are committed to delivering. --- # The Coenzyme That Runs Out > NAD+ powers the chemistry that keeps you alive, and your supply quietly collapses in your 40s. Injectable replacement has become longevity's most-asked-about therapy. URL: https://joinpru.com/blog/nad-the-coenzyme-that-runs-out Issue No. 08 Topic: Science Published: 2026-04-27 Read time: 5 min # The CoenzymeThat Runs Out NAD+ powers the chemistry that keeps you alive, and your supply quietly collapses in your 40s. Injectable replacement has become longevity's most-asked-about therapy. NAD+ is not a name most people recognize. It does not get talked about on cable news. It is not in the supplement aisle next to vitamin C. But every cell in your body uses it. Without it, your mitochondria stop working, your DNA repair stops working, your basic energy chemistry stops working, and you stop working. That should be the end of the story. Your body makes NAD+. Your body uses NAD+. The system runs. Except it does not, exactly. Sometime in your forties, your NAD+ levels begin to fall. By the time you are seventy, the levels in many tissues are roughly half what they were at twenty. The reasons are still being worked out. The trend is well-documented. And it is the reason injectable NAD+ has become one of the most-asked-about therapies in longevity medicine. ## What NAD+ actually does NAD+ stands for nicotinamide adenine dinucleotide. It is a small molecule, a coenzyme, found in every living cell. It exists in two forms: an oxidized form, called NAD+, and a reduced form, called NADH. The cell flips it back and forth as part of the chemical reactions that produce energy. In the simplest terms, NAD+ is how your cells move electrons. Every food molecule you eat is broken down through a series of reactions. Many of those reactions transfer electrons. NAD+ accepts the electrons (becoming NADH). NADH then carries them to the mitochondria, where they are used to generate ATP, the body's energy currency. Without NAD+, the entire chain of reactions that turns food into useable energy stops. That is only the metabolism side. NAD+ also acts as a substrate for several other classes of enzymes that govern DNA repair, gene expression, mitochondrial maintenance, and the cellular stress response. Different enzymes, different jobs, same molecule. ## The decline Cellular NAD+ levels are not stable across a lifespan. They drop. Studies in human tissues, including skin, liver, and skeletal muscle, have documented age-related decline. The exact magnitude varies by tissue and by which form of NAD is measured, but the pattern is consistent. Younger tissues have more NAD+. Older tissues have less. The mechanisms that drive the decline are not fully resolved, but the leading candidates are clear. One is increased activity of an enzyme called CD38, which consumes NAD+ at higher rates as immune cells become more active with age. Another is the accumulated DNA damage of normal living, which activates PARP enzymes that consume NAD+ as they repair the damage. A third is reduced synthesis of NAD+ from its dietary precursors. Aging, in this view, is partly a story of NAD+ being burned faster than it can be made. ## Why this matters for the rest of the body Falling NAD+ has cellular consequences. Mitochondrial function declines because the redox cycling slows. Sirtuin activity falls, because sirtuins require NAD+ to function. DNA damage accumulates, because the repair enzymes that fix it are competing with sirtuins for the same shrinking pool. Each of these changes maps onto features of biological aging that have been documented for decades, including loss of muscle quality, declining metabolic flexibility, and reduced exercise tolerance. This is why NAD+ has attracted the attention it has. The hypothesis, supported by a growing experimental literature, is that restoring cellular NAD+ levels can slow or partially reverse some of the age-related decline in cellular function. NAD+ and NADH cycle continuously in mitochondria to convert food into ATP, the body's energy currency. Seven sirtuin enzymes (SIRT1 through SIRT7) require NAD+ to regulate DNA repair, gene expression, and mitochondrial maintenance. PARP enzymes use NAD+ to repair the DNA breaks that accumulate from radiation, chemicals, and the byproducts of normal metabolism. CD38 is the major consumer of NAD+ in immune cells. Its activity rises with age, accelerating NAD+ depletion in older tissues. ## How it gets replaced Three approaches have emerged for raising NAD+ in the body. The first is dietary precursors: niacin (vitamin B3), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN). These are taken as oral supplements and are converted to NAD+ inside cells. Human trials have shown that NR and NMN can raise blood NAD+ levels, though the magnitude and durability vary across studies. The second approach is direct injection or intravenous infusion of NAD+. This is what most longevity-clinic protocols use. The molecule is administered as a compounded preparation, often by subcutaneous injection or by IV. The pharmacokinetics differ from oral precursors: blood levels rise faster, and the dose can be controlled precisely. The third approach is to slow the consumption of NAD+, primarily by inhibiting CD38. This is the most experimental of the three strategies, with most data still coming from animal studies. Aging, in this view, is partly a story of NAD+ being burned faster than it can be made. Aging, in this view, is partly a story of NAD+ being burned faster than it can be made. ## Why injectable For most patients, the choice between oral and injectable NAD+ is not theoretical. It is a question of bioavailability and dosing. Oral precursors are convenient and inexpensive but rely on the body's own enzymes to convert them, and the conversion can be partial. Injectable NAD+ skips the conversion entirely. The molecule that the cell uses is the molecule that arrives. This is why the longevity-medicine community has increasingly converged on injection as the preferred route for patients who want measurable changes in tissue NAD+ levels. The trade-off is that injectable NAD+ has to be sourced from a state-licensed compounding pharmacy. There is no over-the-counter version. The 503A compounding infrastructure that has matured over the last decade is what makes the injectable option practical for individual patients. ## What we know and what we don't The science of NAD+ has matured rapidly. The decline with age is well-documented. The metabolic role is settled. The sirtuin connection is established. What is less settled is the size of the clinical effect from NAD+ replacement in healthy adults, and how long it lasts. Several human trials are underway. The early signals are encouraging but not yet definitive at the scale of the GLP-1 trials. This is the honest middle: NAD+ is a real molecule with a real cellular role that really does decline with age. The therapy that follows is supported by the biology and is being characterized clinically. The frontier is mature enough to be safe and tested, and not yet mature enough to make breathless promises. ## Where pru sits in the NAD+ conversation At pru, NAD+ is one of the longevity therapies on our formulary because the science is strong enough to defend and the patient experience is well-characterized enough to deliver responsibly. The molecule is compounded at a 503A licensed pharmacy. Each batch ships with a Certificate of Analysis. The dose is matched to the patient. The chemistry that has been keeping you alive since you were born can be supported, when the body's supply begins to fall, by the same molecule the body has always used. That is what responsible longevity medicine looks like. It is what we are committed to delivering. ### Sources & further reading - Massudi, H., Grant, R., Braidy, N., et al. (2012). "Age-Associated Changes in Oxidative Stress and NAD+ Metabolism in Human Tissue." PLoS ONE 7(7): e42357. - Yoshino, J., Baur, J. A., & Imai, S. (2018). "NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR." Cell Metabolism 27(3): 513–528. - Verdin, E. (2015). "NAD+ in aging, metabolism, and neurodegeneration." Science 350(6265): 1208–1213. - Camacho-Pereira, J., Tarragó, M. G., Chini, C. C. S., et al. (2016). "CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction Through an SIRT3-Dependent Mechanism." Cell Metabolism 23(6): 1127–1139. - Imai, S., & Guarente, L. (2014). "NAD+ and sirtuins in aging and disease." Trends in Cell Biology 24(8): 464–471. - Rajman, L., Chwalek, K., & Sinclair, D. A. (2018). "Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence." Cell Metabolism 27(3): 529–547. - Martens, C. R., Denman, B. A., Mazzo, M. R., et al. (2018). "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nature Communications 9: 1286. - Yoshino, M., Yoshino, J., Kayser, B. D., et al. (2021). "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science 372(6547): 1224–1229. - Bonkowski, M. S., & Sinclair, D. A. (2016). "Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds." Nature Reviews Molecular Cell Biology 17(11): 679–690. --- # From Vial to Receptor > Follow a single peptide molecule from your injection site to the cellular receptor it was designed to find, and what happens in the seconds after it locks on. URL: https://joinpru.com/blog/vial-to-receptor Issue No. 07 Topic: Foundations Published: 2026-04-20 Read time: 5 min # From Vialto Receptor Follow a single peptide molecule from your injection site to the cellular receptor it was designed to find, and what happens in the seconds after it locks on. Pick up a vial of any compounded peptide. Read the label. The dose is in micrograms. The volume is in milliliters. The instruction is to inject a tiny amount under the skin. What follows that injection, in the next thirty seconds and the next thirty minutes, is one of the most precise sequences of biology your body performs. This is the story of one molecule. It starts in the syringe and ends at a receptor on a cell that was waiting for exactly this signal. ## The injection The needle goes through skin into the layer of fatty tissue underneath, the subcutaneous space. The plunger pushes a small bolus of fluid into a region rich with two kinds of vessels: capillaries, which are tiny blood vessels with leaky walls, and lymphatic vessels, which collect fluid from tissues and return it to the circulation. Smaller peptides enter the capillaries directly. Larger peptides travel through the lymphatic system first. Either way, within minutes, the molecule is in your bloodstream. ## The bloodstream In the blood, your peptide is one molecule among many. Cardiac output moves about five liters of blood every minute, which means the entire blood volume passes through the heart roughly once a minute. From the heart, the blood is sent to the lungs, then back to the heart, then out through the arteries to every tissue. Your peptide rides along. How long it survives depends on its chemistry. Native peptides like your own GLP-1 are degraded within minutes by enzymes called peptidases. Modified peptides, like semaglutide, attach a fatty acid that lets them bind to albumin, the most abundant protein in your blood. Bound to albumin, semaglutide can survive in circulation for about a week. The body's clearance machinery cannot reach it as easily. ## The capillary, then the cell surface Eventually your molecule reaches the target tissue. Capillaries throughout the body are lined with endothelial cells, and the walls of those capillaries vary in how permeable they are. In organs like the liver, the gaps are wide. In organs like the brain, the gaps are tight. The peptide diffuses through whichever pathway its receptor demands. Outside the capillary now, in the interstitial fluid surrounding cells, the peptide encounters the cell surface. It is looking for one specific feature: a receptor that fits its shape. Receptors are proteins embedded in the cell membrane. Each receptor has a binding pocket designed for a specific signal. The largest single family of receptors, called G protein-coupled receptors or GPCRs, contains around eight hundred members in the human genome. Most peptide hormones bind to receptors in this family. The journey, in five stages ## The lock-on Binding is fast. The peptide approaches the receptor at thermal speed, finds the right shape, and locks into place in milliseconds. The receptor changes shape in response. This is not a static lock-and-key. It is closer to a handshake: both the peptide and the receptor adjust to fit each other better. Biochemists call this induced fit, and it has been the working model of receptor binding for more than half a century. The shape change in the receptor is what makes everything else possible. The receptor sits across the cell membrane, with one part outside the cell and another part inside. When the outside part changes shape, the inside part changes shape too. The cell now knows that something has bound to its surface. The signal has crossed. The peptide reaches the cell surface and finds the receptor whose binding pocket fits its shape. Peptide and receptor settle into a complementary fit. The receptor's shape changes on both sides of the membrane. The shape change activates a G protein, which sets off a chain reaction of second messengers inside the cell. ## The cascade Most peptide receptors belong to the GPCR family. When the receptor changes shape, it activates an attached protein on the inside of the cell, called a G protein. The G protein activates an enzyme. The enzyme produces a small molecule called a second messenger, often cyclic AMP. The second messenger activates other enzymes. Those enzymes alter the activity of dozens of proteins in the cell. This is amplification. One peptide molecule, binding once, triggers a chain of events that multiplies the signal a hundredfold or more. Within seconds, the cell has changed what it is doing. Insulin is released from a beta cell. Hunger fades from a hypothalamic neuron. A growth signal is broadcast to neighboring cells. A blood vessel relaxes. One peptide. One receptor. A signal amplified a hundredfold in the seconds after they meet. One peptide. One receptor. A signal amplified a hundredfold in the seconds after they meet. ## The end of the signal The peptide does not stay bound forever. It eventually dissociates from the receptor, or the receptor pulls the entire complex inside the cell, where the peptide is broken down by intracellular enzymes. The receptor either recycles back to the membrane surface or is itself degraded. The blood concentration of free peptide falls. Other receptors stop being activated. The signal fades. A short-acting peptide like native GLP-1 has a useful biological window of a few minutes. A modified peptide like semaglutide has a window of about a week. The chemistry of each peptide is engineered to land in a specific window for a specific therapeutic purpose. ## Why this matters Peptide therapy is precision medicine in the most literal sense. The molecule is engineered to bind a specific receptor at a specific concentration for a specific duration. Every part of the journey from skin to receptor is governed by physics and chemistry that have been studied for more than a hundred years. None of it is guesswork. At pru, the prescription you receive has been written for the receptor you need to reach. The molecule has been compounded to a tested standard. The dose has been chosen to land in the biological window where it does what it is supposed to do. The vial in your refrigerator is a delivery system for a conversation your cells already know how to have. ### Sources & further reading - Pierce, K. L., Premont, R. T., & Lefkowitz, R. J. (2002). "Seven-transmembrane receptors." Nature Reviews Molecular Cell Biology 3(9): 639–650. - Lefkowitz, R. J. (2013). "A Brief History of G-Protein Coupled Receptors (Nobel Lecture)." Angewandte Chemie International Edition 52(25): 6366–6378. - Hauser, A. S., Attwood, M. M., Rask-Andersen, M., et al. (2017). "Trends in GPCR drug discovery: new agents, targets and indications." Nature Reviews Drug Discovery 16(12): 829–842. - Porter, C. J. H., & Charman, S. A. (2000). "Lymphatic transport of proteins after subcutaneous administration." Journal of Pharmaceutical Sciences 89(3): 297–310. - Lau, J., Bloch, P., Schäffer, L., et al. (2015). "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide." Journal of Medicinal Chemistry 58(18): 7370–7380. (Albumin-binding fatty-acid modification.) - Lau, J. L., & Dunn, M. K. (2018). "Therapeutic Peptides: Historical Perspectives, Current Development Trends, and Future Directions." Bioorganic & Medicinal Chemistry 26(10): 2700–2707. - Drucker, D. J. (2018). "Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1." Cell Metabolism 27(4): 740–756. - Koshland, D. E. (1958). "Application of a Theory of Enzyme Specificity to Protein Synthesis." Proceedings of the National Academy of Sciences 44(2): 98–104. (Original induced-fit model.) - Nelson, D. L., & Cox, M. M. Lehninger Principles of Biochemistry, 8th ed. W. H. Freeman, 2021. (Receptor signaling and second-messenger cascades.) --- # 503A vs 503B > Two short numbers in federal pharmacy law are the reason peptides come from compounders instead of CVS, and the reason your prescription has to be written a specific way to be filled at all. URL: https://joinpru.com/blog/503a-vs-503b Issue No. 06 Topic: Regulatory Published: 2026-04-13 Read time: 5 min # 503A vs 503B Two short numbers in federal pharmacy law are the reason peptides come from compounders instead of CVS, and the reason your prescription has to be written a specific way to be filled at all. Walk into a CVS in any city and ask for a vial of semaglutide compounded for your specific dose. You will be told, with some bewilderment, that they do not do that. They cannot do that. The chemistry is straightforward. The reason it cannot happen at a chain pharmacy is not chemistry. It is law. Two sections of the Federal Food, Drug, and Cosmetic Act, written years apart and forced to grow up by an outbreak that killed sixty-four people, decide where your peptide can be made and who is allowed to make it. They are called Section 503A and Section 503B. Together they describe the entire universe of compounded medications in the United States. Together they decide whether the peptide in your refrigerator is medicine or something else. ## What "compounding" actually means A compounded drug is a medication prepared for a specific patient by a licensed pharmacy, usually because the manufactured version does not exist or does not meet that patient's needs. A child who cannot swallow a tablet might need the drug in liquid form. A patient allergic to a dye in a commercial product might need a dye-free version. A peptide therapy, dosed precisely for one patient and not produced as a finished commercial drug, is compounded. This is an old practice. American pharmacy was almost entirely compounding until industrial pharmaceutical manufacturing took over in the twentieth century. What modern law had to do was draw clear lines around it: who can compound, for whom, at what scale, and to what standards. Section 503A and Section 503B are those lines. ## 1997, 2012, 2013 The first formal compounding framework was the FDA Modernization Act of 1997. It carved out an exemption from full drug-manufacturer regulation for pharmacies that compounded individual prescriptions. That exemption became Section 503A. For the next fifteen years, it described essentially all of legitimate compounding in the United States. In 2012, a Massachusetts pharmacy called the New England Compounding Center shipped contaminated methylprednisolone injections to clinics in twenty-three states. Sixty-four patients died from fungal meningitis. Seven hundred and ninety-three more became seriously ill. The pharmacy's owner was eventually convicted on federal charges. The outbreak made it clear that 503A had been written for a smaller world, one in which compounding pharmacies prepared individual prescriptions rather than industrial-scale batches shipped in bulk. Congress responded the next year with the Drug Quality and Security Act of 2013. The law added a second category, Section 503B, for facilities that compound at scale without patient-specific prescriptions. The two sections, taken together, became the law that governs every legitimate compounded vial in the country. ## 503A: the patient-specific compounder A 503A pharmacy compounds medications for individual named patients with valid prescriptions. Every vial leaving the pharmacy carries a prescription label showing the patient's name, the prescriber, the dose, and the expiration date. State boards of pharmacy regulate 503A pharmacies as their primary oversight body. The FDA also has authority, especially when interstate shipping crosses certain volume thresholds, but day-to-day inspection happens at the state level. Sterile compounded products, including all injectable peptides, must be made under USP General Chapter 797, which sets requirements for cleanroom design, air-quality testing, sterilization, personnel training, and final-product release. Each batch is documented. Each prescription is filled against a specific patient's record. This is where the great majority of compounded peptides for individual patients come from in the United States. ## 503B: the outsourcing facility A 503B facility, formally called an outsourcing facility, compounds at scale without patient-specific prescriptions. The customer is typically a clinic or hospital that needs office-stock supply rather than a single named patient. To make this legal, 503B facilities must operate under Current Good Manufacturing Practice standards, the same framework used by industrial pharmaceutical manufacturers. They are inspected by the FDA directly, on a published schedule, the way a manufacturer is inspected. 503B facilities can ship interstate without the volume limits that apply to 503A pharmacies. They register voluntarily with the FDA and submit production reports. The standards are higher, the federal oversight is more direct, and the volume per facility is much larger. ## Why the distinction matters for your prescription Two practical things follow from this legal architecture. First, your peptide prescription has to be written specifically for you, by a licensed clinician, to be filled at a 503A pharmacy. There is no "self-prescribed" route, and the absence of a prescription is what legally distinguishes a compounded medication from a "research grade" chemical. Second, the pharmacy that fills your prescription has a name, a license, an inspection record, and a state board accountable for its conduct. Any of this can be audited if you want to. Both of these are features, not friction. They are the reason a compounded peptide is treated as medicine and the reason your name is on the label. The two short numbers, 503A and 503B, are the entire architecture of legitimate compounded medicine in the United States. The two short numbers, 503A and 503B, are the entire architecture of legitimate compounded medicine in the United States. ## Where pru sits in this framework At pru, every prescription is filled at a state-licensed 503A pharmacy that we have evaluated in detail. The pharmacy has a name. The pharmacy has a license number. The pharmacy is inspected by its state board. Each batch ships with a Certificate of Analysis. We chose 503A as the framework for individual patient prescriptions because that is what the law was designed for, and because the level of patient-specific care it requires is the level we want delivered to every pru patient. The two short numbers are the entire architecture. They explain why CVS does not sell peptides, why your prescription has to be written a specific way, and why the pharmacy filling it is named, licensed, and accountable. The next time you read a vial label, those numbers are the reason it says what it says. ### Sources & further reading - U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. fda.gov/drugs/human-drug-compounding. - Drug Quality and Security Act of 2013. Public Law 113-54. Codified at 21 U.S.C. §§ 353a (Section 503A) and 353b (Section 503B). - FDA Modernization Act of 1997. Public Law 105-115. Original statutory creation of the 503A compounding exemption. - Smith, R. M., Schaefer, M. K., Kainer, M. A., et al. (2013). "Fungal Infections Associated with Contaminated Methylprednisolone Injections." New England Journal of Medicine 369: 1598–1609. (Canonical publication on the 2012 NECC outbreak.) - United States Pharmacopeia. General Chapter 797: Pharmaceutical Compounding, Sterile Preparations. Current revision. - United States Pharmacopeia. General Chapter 795: Pharmaceutical Compounding, Non-sterile Preparations. Current revision. - U.S. Food and Drug Administration. Registered Outsourcing Facilities (Section 503B). fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities. - U.S. Food and Drug Administration. Current Good Manufacturing Practice (CGMP) Regulations. 21 CFR Parts 210 and 211. - Centers for Disease Control and Prevention. Multistate Fungal Meningitis Outbreak Investigation, 2012–2013. cdc.gov. --- # Where Andrew Huberman Lands on Peptides > The Stanford neuroscientist's public positions on growth hormone secretagogues, GLP-1s, and longevity peptides, held up against the actual literature. URL: https://joinpru.com/blog/andrew-huberman-on-peptides Issue No. 05 Topic: Culture Published: 2026-04-06 Read time: 5 min # Where Andrew HubermanLands on Peptides The Stanford neuroscientist's public positions on growth hormone secretagogues, GLP-1s, and longevity peptides, held up against the actual literature. For an enormous number of Americans, the first time they heard the word peptide was on the Huberman Lab podcast. Andrew Huberman is a tenured Associate Professor of Neurobiology and Ophthalmology at Stanford University School of Medicine, a researcher with a published lab record, and the host of one of the most popular science podcasts in the world. The combination of credentials and audience has given him a singular role in the contemporary peptide conversation. Anyone trying to understand that conversation has to reckon with where Huberman lands on it. The shorter version: he is interested, he is cautious, and he is consistent about pointing his listeners back to the published literature. That posture, more than any single take he has shared, is the most useful thing he has contributed to the public understanding of the field. ## How Huberman frames peptides Across his publicly available podcast episodes, Huberman applies a consistent framework when discussing peptide therapies. The framework can be summarized as four questions: What does the molecule do, mechanistically? What does the human evidence look like? What do we know about long-term safety? And what do we not know? This is the framework most clinicians use, and it produces what the responsible part of the field has been saying for years: peptide medicine is one of the most promising frontiers in biomedicine, and the rigor with which we use it has to match the promise. The Huberman commentary is not always the popular take. It is, in our view, the right one. The receptor it binds, the cells it activates, and the response a clinician can predict in a real patient. How large the effect is in actual patients, how long it lasts, and how it compares to doing nothing. Outcomes measured in years rather than months. Heart, cancer, and hormonal balance: the endpoints that take time to read accurately. The questions where the honest answer is "we are still finding out." Naming them is what separates rigor from guesswork. ## Growth hormone secretagogues Growth hormone secretagogues, including sermorelin, CJC-1295, ipamorelin, and tesamorelin, do not deliver growth hormone directly. They tell the pituitary gland to make more of its own, in pulses that broadly resemble what your body produced when you were younger. The mechanism is the same one your body has used since it was built. The intervention is to ask the body to do something it already knows how to do. Tesamorelin is FDA-approved for HIV-associated lipodystrophy and has a well-characterized safety database in that population. The others are used clinically off-label, with growing evidence and a longer human safety record forming each year. Huberman's commentary on this category lands where the literature does: real mechanism, plausible benefit, and an active frontier of clinical research that responsible practitioners are watching closely. ## GLP-1 receptor agonists On GLP-1 receptor agonists, semaglutide and tirzepatide, the framework yields its most confident answers, because the human evidence base is unusually strong. The STEP and SURMOUNT trial families, published in the New England Journal of Medicine, document mean weight loss of 14.9 percent for semaglutide at sixty-eight weeks and 20.9 percent for tirzepatide at seventy-two weeks. Side effects are documented. Side effects are tolerable for most patients. The drugs have already changed the trajectory of the obesity and diabetes epidemics in measurable ways. Where Huberman's commentary adds value to the public conversation is on the mechanism side, especially the role of GLP-1 in central nervous system regulation of appetite, which is an area of his own field. The science here is mature. The framework yields a clear and supportive read of the evidence. ## BPC-157, the frontier case BPC-157, sometimes referred to by the longer name Body Protection Compound 157, is the peptide most likely to come up in casual conversation about tissue repair. The animal evidence is genuinely promising. Healing accelerates. Tendons, gut tissue, and skin all respond. The mechanism involves angiogenesis (the formation of new blood vessels), and that mechanism is also why the field is taking the time to assemble the long-term human data before recommending it broadly. New blood-vessel formation is a feature in healing, and a question worth answering carefully for any cells that should not be growing. Huberman has discussed this thoughtfully in publicly available episodes. The version of the framework here is forward-looking: the science is promising, the human evidence is still arriving, and the discipline of waiting for it is what separates a serious clinical practice from a wellness storefront. This is exactly the kind of category pru watches closely, with protocols ready to deploy on the day the evidence base meets the bar we set for our formulary. Peptide medicine is one of the most promising frontiers in biomedicine. The rigor with which we use it has to match the promise. Peptide medicine is one of the most promising frontiers in biomedicine. The rigor with which we use it has to match the promise. ## Where his commentary lands relative to the literature For listeners, the practical takeaway from the Huberman canon on peptides is not a list of products. It is a posture: understand what the evidence shows, act where it is strongest, and watch closely where it is still being written. That posture is what responsible peptide medicine looks like, and it is the same posture pru is built on. The peptide conversation is bigger than any one figure. But for an audience of millions, Huberman has been one of the most consistent public voices pushing the conversation toward primary sources. The rest of the field can either match that standard or fall behind it. At pru, every therapy on our formulary is supported by peer-reviewed evidence and prescribed by a licensed clinician who can answer the four framework questions for the specific molecule, the specific dose, and the specific patient. We did not invent the science. Our job is to deliver it with the trust and transparency the science deserves, and to expand the formulary only when the evidence supports it. That is what the frontier of responsible peptide medicine looks like, and it is what we are committed to delivering. ### Sources & further reading - Stanford School of Medicine. Huberman Laboratory. hubermanlab.stanford.edu. (Faculty appointment and lab page.) - Huberman Lab Podcast. hubermanlab.com. (Publicly available episode catalog covering peptides, longevity, and metabolic health.) - Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." New England Journal of Medicine 384: 989–1002. - Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." New England Journal of Medicine 387: 205–216. - Falutz, J., Allas, S., Blot, K., et al. (2007). "Metabolic effects of a growth hormone-releasing factor in patients with HIV." New England Journal of Medicine 357: 2359–2370. (Tesamorelin pivotal trial.) - Sigalos, J. T., & Pastuszak, A. W. (2018). "The Safety and Efficacy of Growth Hormone-Releasing Peptides in Men." Sexual Medicine Reviews 6(1): 45–53. - Sikiric, P., Seiwerth, S., Rucman, R., et al. (2014). "Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications." Current Neuropharmacology 12(2): 147–158. - Drucker, D. J. (2018). "Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1." Cell Metabolism 27(4): 740–756. - Bartke, A., List, E. O., & Kopchick, J. J. (2016). "The somatotropic axis and aging: Benefits of endocrine defects." Growth Hormone & IGF Research 27: 41–45. (Long-term IGF-1 elevation and longevity considerations.) --- # Why GLP-1 Works When Willpower Doesn't > Semaglutide and tirzepatide rewire the brain's hunger signals at the receptor level: a quieter, more honest answer to why the GLP-1 era arrived so suddenly. URL: https://joinpru.com/blog/glp1-and-willpower Issue No. 04 Topic: Science Published: 2026-03-30 Read time: 5 min # Why GLP-1 WorksWhen Willpower Doesn't Semaglutide and tirzepatide rewire the brain's hunger signals at the receptor level: a quieter, more honest answer to why the GLP-1 era arrived so suddenly. Most weight-loss advice ends with the same idea: try harder. Eat less. Move more. Use better discipline. The advice has been repeated so often that it has become the default explanation for why some people stay lean and others do not. The advice is also, in most cases, wrong about the biology. Hunger is not a feeling that floats around in your head, waiting for you to override it. It is a signal generated by hormones, sent to your brain, and processed by neurons that were tuned by evolution to make sure you do not starve. The signal has volume. The signal has duration. And the signal can be turned down. That is what GLP-1 receptor agonists do. They turn down the signal. Not by acting on willpower, which they cannot, but by acting at the level of the receptor where the hunger signal is heard. ## What GLP-1 actually is GLP-1 stands for glucagon-like peptide 1. It is a thirty-amino-acid peptide hormone your body makes throughout the day, mostly from L-cells lining your small intestine. When food arrives in the gut, those cells release GLP-1 into the bloodstream. The hormone reaches the pancreas, where it tells the pancreas to release insulin. It reaches the stomach, where it slows the rate at which the stomach empties. It reaches the brain, where it tells the brain that food has arrived and the meal can end. This is the system that decides, on your behalf, when you are full. You do not have to think about it. It runs whether you are paying attention or not. And in some bodies, for reasons that include genetics, age, prior dieting history, and chronic disease, the system runs at lower volume than is optimal. The signal to stop eating arrives quieter, later, or both. ## How the drugs differ from your own GLP-1 Your own GLP-1 has a problem as a drug: it lasts about two minutes in the bloodstream before being broken down by an enzyme called DPP-4. To make a usable therapy, scientists modified the molecule. The changes were small but consequential. They added a few amino-acid substitutions and a fatty-acid tail that lets the modified peptide bind to albumin in the blood. The result was a peptide that acts on the same receptor as your own GLP-1 but lasts about a week instead of two minutes. Semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for obesity, was the first such drug to reach broad use. Tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, goes one step further. It activates two receptors at once, GLP-1 and a related receptor called GIP. The dual action produces stronger effects on both blood sugar and body weight. L-cells lining the small intestine release GLP-1 into the bloodstream after a meal arrives. Stimulates glucose-dependent insulin release and suppresses glucagon, lowering blood sugar. Delays the rate at which food leaves the stomach, prolonging the sensation of fullness. Activates POMC satiety neurons in the arcuate nucleus, generating fullness upstream of conscious thought. ## The brain mechanism, in detail The brain mechanism is what makes GLP-1 receptor agonists feel different from older weight-loss drugs. Your hypothalamus is the region of your brain that regulates basic drives like hunger, thirst, and body temperature. Inside it, two opposing groups of neurons compete to set your appetite. One group, called POMC neurons, produces fullness when active. The other group, called AgRP neurons, produces hunger when active. GLP-1 receptors sit on the POMC neurons. When the receptor is activated by your own GLP-1 or by an injected analog like semaglutide, fullness is generated before you decide to think about it. Older weight-loss drugs worked by stimulating the central nervous system or by blocking fat absorption. They produced side effects that were often difficult to tolerate and benefits that were modest. GLP-1 receptor agonists work by mimicking a hormone the body already uses, on a circuit the body already runs. The drug does not invent new biology. It increases the volume on a signal that was already there. ## What the clinical trials show In the STEP 1 trial, published in the New England Journal of Medicine in 2021, adults with overweight or obesity who received weekly semaglutide for sixty-eight weeks lost on average 14.9 percent of their body weight. The placebo group lost 2.4 percent. The trial enrolled 1,961 patients. In SURMOUNT-1, published in the same journal in 2022, adults receiving the highest dose of tirzepatide lost on average 20.9 percent of their body weight at seventy-two weeks. The placebo group lost 3.1 percent. The trial enrolled 2,539 patients. The numbers are larger than what most weight-loss drugs have produced over the entire history of the drug class. GLP-1 receptor agonists do not work because they make people stronger. They work because they fix a signal. GLP-1 receptor agonists do not work because they make people stronger. They work because they fix a signal. ## What this teaches us For decades, the dominant cultural framing of body weight has been that fat people lack discipline. The framing has been moralized in advertising, in medicine, and in casual conversation. The framing has also failed, repeatedly, to predict outcomes. Diets work in the short term and fail in the long term. Patients regain weight even when they continue trying. The biology pulls them back. GLP-1 receptor agonists do not work because they make people stronger or more disciplined. They work because they correct a signal that, for many bodies, was running too quietly. The willpower framing was never describing the right system. The hormone was. Both semaglutide and tirzepatide are available through pru, prescribed by a licensed clinician, compounded at a 503A licensed pharmacy, and accompanied by a Certificate of Analysis on every batch. The science is not ours. The standards we deliver it under are. ### Sources & further reading - Drucker, D. J. (2018). "Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1." Cell Metabolism 27(4): 740–756. - Müller, T. D., Finan, B., Bloom, S. R., et al. (2019). "Glucagon-like peptide 1 (GLP-1)." Molecular Metabolism 30: 72–130. - Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." New England Journal of Medicine 384: 989–1002. - Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." New England Journal of Medicine 387: 205–216. - Lau, J., Bloch, P., Schäffer, L., et al. (2015). "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide." Journal of Medicinal Chemistry 58(18): 7370–7380. - Coskun, T., Sloop, K. W., Loghin, C., et al. (2018). "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept." Molecular Metabolism 18: 3–14. - Andermann, M. L., & Lowell, B. B. (2017). "Toward a Wiring Diagram Understanding of Appetite Control." Neuron 95(4): 757–778. (POMC and AgRP neuron circuitry.) - Secher, A., Jelsing, J., Baquero, A. F., et al. (2014). "The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss." Journal of Clinical Investigation 124(10): 4473–4488. --- # "Research Grade" Is Not What You Think > Two words on a vial label decide whether what you're injecting is medicine or an unregulated chemical. It's important you tell the difference. URL: https://joinpru.com/blog/research-grade Issue No. 03 Topic: Foundations Published: 2026-03-23 Read time: 4 min # "Research Grade"Is Not What You Think Two words on a vial label decide whether what you're injecting is medicine or an unregulated chemical. It's important you tell the difference. Look at any peptide vial sold online. Buried in fine print, you will see one of two phrases. The first says "For Research Use Only" or "Not For Human Consumption." The second says nothing of the sort, because it is a prescription drug, dispensed from a licensed pharmacy. Those two phrases describe two completely different products, governed by two completely different sets of rules, made to two completely different standards. The molecules might share a name. Almost nothing else about them does. ## What "research grade" actually means The phrase research grade sounds technical and rigorous. In practice, it is the opposite. Under United States law, a substance labeled "for research use only" is not regulated as a drug by the FDA. The seller is making a legal claim: this is a chemical for laboratory experiments, not a medicine for people. That single claim does an enormous amount of work. It exempts the product from the testing, sterility, purity, and labeling rules that govern medicine. Translated: when you buy a vial labeled "research grade," you are buying something that has not been required to be tested for purity, sterility, identity, or dose. The seller is not required to verify that the peptide inside is what the label says it is. The seller is not required to ensure it is uncontaminated by bacteria, endotoxins, or unrelated chemicals. The seller is not required to make sure the dose is anything close to the labeled amount. None of those guarantees apply, because legally, it is not medicine. ## What medical grade actually means Medical-grade peptides come from a different world. They are compounded at a state-licensed 503A pharmacy under federal law passed in 2013, the Drug Quality and Security Act. Compounding pharmacies operate under USP General Chapter 797, which sets sterility standards for injectable preparations. Each batch is tested for identity (high-performance liquid chromatography and mass spectrometry), purity, sterility, and endotoxin levels. Each batch ships with a Certificate of Analysis showing those test results. Each prescription is filled against a written order from a licensed physician for a specific named patient. The pharmacy is inspected by both the state board of pharmacy and the FDA. The clinician carries a license. The patient has a chart. The vial has a chain of custody you can audit. - "For Research Use Only" disclaimer label - No FDA oversight as a drug - No required sterility testing - No required identity verification - No required purity testing - No prescription required to purchase - Anonymous online purchase - No chain of custody - Prescription label with patient name - FDA and state pharmacy oversight - USP 797 sterility standards - HPLC and mass spectrometry verification - Certificate of Analysis per batch - Written prescription from a licensed clinician - Named patient on file - Documented chain of custody ## What that means in practice Independent testing of black-market and gray-market peptides has documented wide variation in purity, identity, and contamination. Vials sold under one peptide name have been found to contain a different peptide entirely. Some show bacterial or endotoxin contamination at levels that would not be safe for injection. Some contain little or no active peptide at all. The buyer has no way to know which kind of vial is in their hand without sending it to a lab. Medical-grade peptides exist on the other side of a wall. Each batch's purity, identity, and sterility have been verified by testing before the vial leaves the pharmacy. Each Certificate of Analysis is auditable. Each pharmacy is inspected. The molecules can be chemically identical. Everything around the molecule is what changes. The molecules can be chemically identical. Everything around the molecule is what changes. ## How to tell the difference You do not need a chemistry degree to read a vial. Three checks will tell you almost everything. Does it have a prescription number, your name, an expiration date, and a licensed pharmacy address? If yes, medical grade. If the label says "Research Use Only," it is not. Did a clinician evaluate your case and write a prescription, or did you click "add to cart" on a website that did not ask who you are? The former is medicine. The latter is not. Is a Certificate of Analysis available? Can you trace the pharmacy that compounded the vial? If yes, medical grade. If no, treat the vial as unknown. The peptide molecules themselves can be genuinely identical between the two grades. Synthesis chemistry does not care who is paying. What is different is everything around the molecule: who tested it, who certified it, who is liable if something goes wrong, who is legally allowed to sell it to you, and whether anyone has any incentive to make sure the vial in your hand is what the label says. That gap is not a technicality. It is the difference between a medicine and an experiment that you have agreed to run on yourself. Every therapy on the pru formulary is medical grade. Each prescription is written by a licensed clinician. Each vial is compounded at a 503A pharmacy. Each batch ships with a Certificate of Analysis. We pay attention to the two words on the vial, because they are the two words that change everything else. ### Sources & further reading - U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. fda.gov/drugs/human-drug-compounding. - Drug Quality and Security Act of 2013. Public Law 113-54, codified at 21 U.S.C. §§ 353a (503A) and 353b (503B). - United States Pharmacopeia. General Chapter 797: Pharmaceutical Compounding, Sterile Preparations. Current revision. - U.S. Food and Drug Administration. Guidance for Industry: Investigational New Drug Applications and "Research Use Only" Labeling. fda.gov. - U.S. Food and Drug Administration. Warning Letters and Untitled Letters to Vendors of Bulk Peptide Products Sold for Research Use. fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters. - National Association of Boards of Pharmacy. Compounding Pharmacy Inspection and Standards Resources. nabp.pharmacy. - U.S. Pharmacopeia. Compounded Preparations: Identity, Strength, Quality, and Purity Standards. usp.org. --- # Why pru Exists > Peptides changed lives before the system caught up to them. pru is the company built to make sure the next generation of patients get them prescribed properly and transparently. URL: https://joinpru.com/blog/why-pru-exists Issue No. 02 Topic: Pru Published: 2026-03-16 Read time: 4 min # Why pru Exists Peptides changed lives before the system caught up to them. pru is the company built to make sure the next generation of patients get them prescribed properly and transparently. Some products reach the people they were built for. Others bounce around the wrong neighborhoods of the internet for fifteen years before anyone notices. Peptides are the second kind. For most of the last decade, the most clinically promising peptide therapies have been bought on shadowy research-chemical websites, mixed in apartment kitchens, and injected by people who did not know what was in the vial. The patients who needed them most were either getting nothing, or getting something dangerous. That is the world pru was built to change. ## What we saw We started pru after watching the same pattern play out, again and again. A patient hears about a peptide on a podcast, or from a doctor who works with athletes. They go looking. What they find is rarely what they need. The most common landing spots are three. The first is a clinic that costs eight thousand dollars a year and bundles peptides alongside testosterone, hair-loss pills, and skincare the patient never asked about. The second is a telehealth brand that lists forty different SKUs on its website but cannot tell you which compounding pharmacy made the vial in your hand. The third is a "research peptides" website that ships from overseas with disclaimers nobody reads, dosage calculators that nobody verifies, and quality controls that do not exist. Meanwhile, the science kept moving. Compounding pharmacies got cleaner. Clinical trials got bigger. The FDA went back and forth, and in February of this year, mostly forth. The case for medically supervised peptide therapy got stronger every quarter. The infrastructure to deliver it, properly, did not. How a peptide reaches you, the pru way ## What pru is built on Three commitments. They are simple to state and harder to keep. We staked the company on all three. Every prescription on pru is written by a licensed physician who reviewed your intake personally. We do not use auto-prescribers. After your first dose, your clinician is reachable, by name, for as long as you are a pru patient. There is no extra fee for messages, follow-ups, or dosing questions, and there is no script that triages you to a different person each time. We publish our cost-plus pricing model. The wholesale price of every vial, the markup we add on top, and where the rest of the money goes are visible to every patient. If the price ever changes, we will tell you why before you ask. pru is built around six focus areas, all of them peptide and longevity therapies. We do not sell testosterone, ED pills, hair loss, skin care, or anything outside that category. Our competitors sell a hundred different SKUs and master none of them. The peptide era deserves a brand that treats the category as the main event, not a sideline. ## What this looks like in practice Pillars are easy to write. They are harder to operationalize. These are the operational guarantees that make ours real. - Unlimited messaging with your clinician, with no extra fee for follow-ups, dosing questions, or check-ins. - Cost-plus pricing on every therapy, with the wholesale cost and markup published openly. - A 6 Category Formulary, with no SKU added unless we can defend it on medical merit. - A 503A licensed compounding pharmacy partner, fully audited, with a documented chain of custody. We are not the first company to sell peptides. We are trying to be the first to sell them the way they should have been sold from the beginning. We are not the first company to sell peptides. We are trying to be the first to sell them the way they should have been sold from the beginning. --- # The Messenger Molecules > Peptides without the jargon: a plain-English explanation of what they actually are, why your body already makes thousands of them, and why a small handful are reshaping modern medicine. URL: https://joinpru.com/blog/the-messenger-molecules Issue No. 01 Topic: Foundations Published: 2026-03-09 Read time: 4 min # The MessengerMolecules Peptides without the jargon: a plain-English explanation of what they actually are, why your body already makes thousands of them, and why a small handful are reshaping modern medicine. Right now, somewhere inside you, a tiny molecule is finding the exact cell it was built to talk to. It floats through your bloodstream past millions of other cells, ignores all of them, and locks onto a single receptor, the way a key fits into a single lock. Once it's there, it tells that cell to do something specific. Burn fat. Repair tissue. Feel hungry. Feel calm. Fall asleep. The molecule is called a peptide. Your body makes thousands of them, every day, your entire life, and a small handful of them are quietly reshaping modern medicine. ## What a peptide actually is A peptide is a chain of amino acids, the same twenty molecular building blocks that, in longer chains, make up every protein in your body. The difference between a peptide and a protein is mostly length. By chemistry's working convention, anything from two to roughly fifty amino acids is called a peptide; anything longer is usually called a protein. Insulin, with fifty-one amino acids in two linked chains, sits right on the border, which is why textbooks sometimes call it a "peptide hormone" and sometimes a "small protein." The reason length matters is that it determines what a molecule can physically do. Proteins are large, structural, and slow-moving. They form muscle fibers, antibodies, and the receptor sites on your cell surfaces. Peptides are smaller, faster, and built to carry messages between cells. From building block to message to machine ## Your body already makes thousands of them The human genome encodes roughly twenty thousand proteins. From those proteins, the body cleaves out a vast library of bioactive peptides. Thousands have been catalogued in scientific databases, with new ones still being discovered. Many of the words you already know are peptides: Peptides You May Already Know Insulin Controls blood sugar 51 amino acids Oxytocin Bonding, social trust, childbirth 9 amino acids Vasopressin Fluid balance, blood pressure 9 amino acids Glucagon Raises blood sugar 29 amino acids GLP-1 The satiety hormone behind Ozempic & Mounjaro 30 amino acids Ghrelin The hunger hormone 28 amino acids GHRH Tells the pituitary to release growth hormone 44 amino acids Beta-endorphin The body's painkiller 31 amino acids Each is a peptide your own body has made constantly since you were born. They are not foreign; they are not synthetic; they are not new to medicine. What is new is the ability to make them outside the body, purely, identically, at scale, and use them therapeutically. ## Why a small handful are reshaping medicine The first peptide drug was insulin, isolated from cattle pancreases in 1921 and given to a dying fourteen-year-old named Leonard Thompson in January 1922. He lived. The era of peptide medicine began with that single injection. For most of the next century, peptide drugs were rare and expensive. Synthesis was difficult; peptides degraded quickly in the bloodstream; they couldn't be taken as pills. Two breakthroughs changed that. The first was Bruce Merrifield's invention of solid-phase peptide synthesis in 1963, a way to manufacture peptides on a chemical scaffold, one amino acid at a time. He won the Nobel Prize for it in 1984. The second was the development of stabilization techniques that let modified peptides survive in the body long enough to actually work. A century of peptide medicine Today there are more than eighty peptide drugs approved by the FDA, with hundreds more in clinical trials. The most famous, by an enormous margin, are the GLP-1 receptor agonists: semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Both are modified versions of natural peptides your body already makes. Semaglutide is so closely related to your own GLP-1 that it differs by only two amino-acid changes and an attached fatty acid, small chemical modifications that let it last about a week in the body instead of the few minutes the natural hormone survives. But the GLP-1s are only the public face of the peptide era. Quietly, in clinics and compounding pharmacies, a wider category of peptides is being used to support tissue repair, growth hormone signaling, sexual function, immune modulation, and cellular aging. Some of these, such as sermorelin, oxytocin, and GHK-Cu, are nearly identical to molecules your body already produces. Others are designed copies of peptides found elsewhere in nature. The common thread is that they are all messengers. They don't push the body to do something it wasn't built to do; they ask it to do something it already knows how to do. The common thread is that they are all messengers. They don't push the body to do something it wasn't built to do; they ask it to do something it already knows how to do. ### Sources & further reading - National Human Genome Research Institute. The Human Genome Project Completion: Frequently Asked Questions. genome.gov. (Approximate count of human protein-coding genes.) - Nelson, D. L., & Cox, M. M. Lehninger Principles of Biochemistry, 8th ed. W. H. Freeman, 2021. (Standard convention for peptide vs. protein length.) - Bliss, M. The Discovery of Insulin. University of Chicago Press, 1982. University of Toronto Banting Digital Library. (Leonard Thompson, January 1922.) - Merrifield, R. B. (1963). "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide." Journal of the American Chemical Society 85(14): 2149–2154. Nobel Prize in Chemistry, 1984. - du Vigneaud, V., et al. (1953). "The Synthesis of an Octapeptide Amide With the Hormonal Activity of Oxytocin." Journal of the American Chemical Society 75: 4879–4880. Nobel Prize in Chemistry, 1955. - Lau, J. L., & Dunn, M. K. (2018). "Therapeutic Peptides: Historical Perspectives, Current Development Trends, and Future Directions." Bioorganic & Medicinal Chemistry 26(10): 2700–2707. - Lau, J., et al. (2015). "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide." Journal of Medicinal Chemistry 58(18): 7370–7380. - UniProtKB Human Reference Proteome and PeptideAtlas (peptideatlas.org). (Catalogued bioactive peptides.)